A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

One man’s trash may be another man’s treasure, but dumpster diving when investing carries risks. You have to wade through a ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...